BioCentury
ARTICLE | Clinical News

Why Vertex picked elexacaftor for CF triple combo regimen

May 30, 2019 8:24 PM UTC

Vertex said it selected elexacaftor (VX-445) as the third component of its cystic fibrosis combination therapy after reporting updated Phase III data on Thursday. The company reiterated its plans to submit an NDA to FDA next quarter and an MAA to EMA in 4Q19 for the CF triple combination therapy.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it chose elexacaftor over VX-659, the other compound it was testing, due to "favorable profiles for safety, tolerability and drug-drug interactions, the ability for co-administration with hormonal contraceptives, and the lack of photosensitivity." Tezacaftor and Kalydeco ivacaftor are the two other components of the triple combination...

BCIQ Company Profiles

Vertex Pharmaceuticals Inc.